The study period per patient was expected to be between 56 and 160 weeks depending on when the patient was randomized and this included the following:
* a screening period up to 4 weeks,
* a treatment period expected to be between 48 and 152 weeks,
* 4-week post rapid elimination follow-up period.
Patients were to continue on treatment until a fixed common end date which was approximately 48 weeks after randomization of the last patient.
For those patients who completed the treatment period, a long term extension study of approximately 1 year (including teriflunomide alone) was initially planned to be proposed.
